Litcius/Paper detail

Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial

Irwin Walker, Tony Panzarella, Stephen Couban, Félix Couture, Gerald M. Devins, Mohamed Elemary, Geneviève Gallagher, Holly Kerr, John Kuruvilla, Stephanie J. Lee, John J. Moore, Thomas J. Nevill, Gizelle Popradi, Jean Roy, Kirk R. Schultz, David Szwajcer, Cynthia L. Toze, Ronan Foley

2020The Lancet Haematology96 citationsDOI

Topics & Concepts

MedicineAnti-thymocyte globulinCumulative incidenceInternal medicineTransplantationGraft-versus-host diseaseHazard ratioSurgeryClinical endpointTacrolimusRandomized controlled trialGastroenterologyConfidence intervalHematopoietic Stem Cell TransplantationRenal Transplantation Outcomes and TreatmentsAcute Myeloid Leukemia Research
Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial | Litcius